Skip to main
LSTA
LSTA logo

LSTA Stock Forecast & Price Target

LSTA Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lisata Therapeutics Inc. shows a strong positive outlook driven by the promising preliminary data from the Cohort A study, which indicated an encouraging trend in overall survival and included four complete responses among patients treated with certepetide. The advancements in the development of certepetide as the company's lead candidate are noteworthy, with data from Cohort B suggesting that a second dose may enhance progression-free survival (PFS) and overall response rate (ORR) for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). These results highlight the therapeutic potential of certepetide in effectively targeting and treating solid tumors, positioning Lisata Therapeutics favorably within the clinical-stage pharmaceutical market.

Bears say

The financial outlook for Lisata Therapeutics Inc is predominantly negative due to the potential for failed or inconclusive results from ongoing clinical trials, which could significantly hinder the company's advancement in the development of its investigational product, certepetide. Additionally, there is a notable concern regarding the company's ability to secure adequate funding necessary to continue its research and development efforts, which poses a further risk to its operational viability. These fundamental challenges highlight the uncertainties surrounding the company's prospects, particularly in a highly competitive therapeutic landscape for the treatment of solid tumors.

LSTA has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lisata Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lisata Therapeutics Inc (LSTA) Forecast

Analysts have given LSTA a Strong Buy based on their latest research and market trends.

According to 2 analysts, LSTA has a Strong Buy consensus rating as of Dec 7, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lisata Therapeutics Inc (LSTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.